UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2017
CONATUS PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-36003 | 20-3183915 |
| (State or Other Jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification No.) |
| 16745 West Bernardo Drive, Suite 200 | ||
| San Diego, CA | 92127 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (858) 376-2600
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Salaries and Bonuses of Executive Officers
On January 26, 2017, the Compensation Committee of the Board of Directors of Conatus Pharmaceuticals Inc. established the base salaries to be paid to the executive officers listed below, effective January 1, 2017, set target cash bonuses for the 2017 fiscal year for each of the executive officers listed below and approved cash bonus payments for the 2016 fiscal year to be paid to each of the executive officers listed below.
The new base salaries, 2017 target cash bonus payments and 2016 actual cash bonus payments are as follows:
| Name | Title | 2017 Base Salary | 2017 Target Cash Bonus | 2016 Actual Cash Bonus | ||||||||||
| Steven J. Mento, Ph.D. | President and Chief Executive Officer | $ | 521,433 | $ | 260,717 | $ | 314,875 | |||||||
| Alfred P. Spada, Ph.D. | Executive Vice President, Research and Development and Chief Scientific Officer | $ | 400,212 | $ | 160,085 | $ | 185,605 | |||||||
| David T. Hagerty, M.D. | Executive Vice President, Clinical Development | $ | 402,781 | $ | 161,112 | $ | 186,797 | |||||||
| Charles J. Cashion | Senior Vice President, Finance, Chief Financial Officer and Secretary | $ | 339,112 | $ | 118,689 | $ | 137,610 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 1, 2017 | CONATUS PHARMACEUTICALS INC. | ||
| By: | /s/ Charles J. Cashion | ||
| Name: | Charles J. Cashion | ||
| Title: | Senior Vice President, Finance, | ||
| Chief Financial Officer and Secretary | |||